

Aug 03, 2025

Drug transporter (SLC) inhibition panel assay using drug substrates

DOI

<https://dx.doi.org/10.17504/protocols.io.3byl41o7rlo5/v1>

Nick Lynch^{1,2}

¹Curlew Research; ²ASAP Discovery Consortium

ASAP Discovery



Nick Lynch

Curlew Research, ASAP Discovery Consortium

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.3byl41o7rlo5/v1>

Protocol Citation: Nick Lynch 2025. Drug transporter (SLC) inhibition panel assay using drug substrates. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.3byl41o7rlo5/v1>

License: This is an open access protocol distributed under the terms of the **[Creative Commons Attribution License](#)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: June 04, 2025

Last Modified: August 03, 2025

Protocol Integer ID: 219517

Keywords: ADME, DMPK, drug discovery, drug transporter, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2-K, Solute Carrier transporters (SLC), inhibitors of these transporter, crucial role in drug absorption, using drug substrates slc, drug substrates slc, drug absorption, drug transporter, drug interaction, inhibitor, altered drug concentration, administered drug, solute carrier, transporter, drug, inhibition panel, toxicity, oat1, inhibition, oat3, absorption, oatp1b1, oatp1b3

Disclaimer

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to [protocols.io](https://www.protocols.io) is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgement, advice, diagnosis, or treatment. Any action you take or refrain from taking, using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with [protocols.io](https://www.protocols.io), can be held

Abstract

SLC (Solute Carrier) transporters play a crucial role in drug absorption, distribution, and elimination. Some drugs can act as inhibitors of these transporters, potentially affecting the absorption or clearance of other co-administered drugs, leading to drug interactions. This can result in altered drug concentrations and potentially affect efficacy or increase toxicity.

Transporters used were OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2-K

Safety warnings

- ⚠ Always wear appropriate PPE for this protocol
Refer to Material Safety Data Sheets for additional safety and handling information.

Summary

- 1 SLC (Solute Carrier) transporters play a crucial role in drug absorption, distribution, and elimination. Some drugs can act as inhibitors of these transporters, potentially affecting the absorption or clearance of other co-administered drugs, leading to drug interactions. This can result in altered drug concentrations and potentially affect efficacy or increase toxicity.
 - **SLC Transporters:**

These are integral membrane proteins that facilitate the transport of various substances, including drugs, across cell membranes. They are involved in both the uptake (influx) and efflux (outflux) of drugs, influencing their absorption, distribution, and excretion.
 - **Drug-Drug Interactions at the Transporter Level:**

Some drugs can bind to SLC transporters and act as inhibitors, preventing the transport of other drugs or co-administered substrates. This can lead to increased drug concentrations in the blood, potentially leading to increased toxicity or decreased efficacy.
 - **Clinical Significance:**

Understanding these drug-transporter interactions is crucial for optimizing drug therapy and minimizing adverse drug reactions. Clinical guidelines often recommend testing for potential OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2-K inhibition due to their role in drug interactions.

Sample Preparation

- 2 Cells are seeded in a 24-well culture plate typically at 150,000 cells/well and are used on days 2 or 3 post-seeding.

Assay

- 3 On the day of assay, the test compound is prepared in assay buffer (HBSS-HEPES, pH 7.4), added to the cell plate, and pre-incubated at 37 °C for 30 min.
- 4 Subsequently substrate is added to the plate followed by 20-min incubation at 37 °C.
- 5 The plate is then washed with cold assay buffer followed by quantification of the transporter specific substrates in the cells using HPLCMS/MS.

- 6 The reference inhibitor is tested in each assay at multiple concentrations to obtain an IC₅₀ value. The peak areas of the transporter specific substrate and an internal control are measured by HPLCMS/MS from each sample.

A	B	C	D
Transporter	Cell line	Substrate	Reference Inhibitor
OATP1B1	OATP1B1-CHO	Estradiol 17-(β -D-glucuronide)	Cyclosporine
OATP1B3	OATP1B3-CHO	Estradiol 17-(β -D-glucuronide)	Cyclosporine
OAT1	OAT1-CHO	p-Aminohippurate	Probenecid
OAT3	OAT3-CHO	Ranitidine	Probenecid
OCT1	OCT1-CHO	TEA	Verapamil
OCT2	OCT2-HEK	Metformin	Verapamil
MATE1	MATE1-HEK	Metformin	Pyrimethamine
MATE2-K	MATE2-K-HEK	Metformin	Pyrimethamine
ASBT	ASBT-HEK	Taurocholic acid	Glycochenodeoxycholate

Data Analysis

- 7 The peak ratio of the peak area of the substrate vs internal control is used as the concentration of the substrate inside the cells.

The percent of inhibition is calculated by,

$$\% \text{ of inhibition} = 100 - [(\text{Compound} - \text{Background}) / (\text{T1} - \text{Background}) \times 100]$$

- Where Compound is the individual peak ratio obtained in the presence of the Test Compound.
- Background is the peak ratio obtained in the presence of the highest test concentration of reference inhibitor, representing the lowest transporter activity.
- T1 is the mean peak ratio obtained in the presence of the substrate without the test or reference compound, representing the highest transporter activity.

The IC50 value is determined by non-linear regression analysis of the concentration-response curve using the Hill equation.

Protocol references

An Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters

<https://doi.org/10.3389/fphar.2021.722889>

Acknowledgements

Grateful to Concept Life Sciences for supplying the original protocol summary